Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-08-11
2003-03-04
Caputa, Anthony C. (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S320100, C435S325000, C435S069100, C435S070100, C530S350000, C530S300000
Reexamination Certificate
active
06528635
ABSTRACT:
TECHNICAL FIELD
The present invention relates to novel tumor antigen proteins and genes encoding the same, and antibodies against said tumor antigen proteins, as well as methods of treating, preventing, or diagnosing tumors using such materials.
BACKGROUND ART
It is known that the immune system, particularly T cells, plays an important role in vivo in tumor rejection. Indeed, infiltration of lymphocytes having cytotoxic effects on tumor cells has been observed in human tumor foci (
Arch. Surg.,
126:200-205, 1990), and cytotoxic T lymphocytes (CTLs) recognizing autologous tumor cells have been isolated from melanomas without great difficulties (e.g.,
Immunol. Today,
8:385, 1987;
J. Immunol.,
138:989, 1987; and
Int. J. Cancer,
52:52-59, 1992). In addition, the results of clinical treatment of melanomas by T cell introduction also suggest the importance of T cells in tumor rejection (
J. Natl. Cancer. Inst.,
86:1159, 1994).
Although it has long been unknown about target molecules for CTLs attacking autologous tumor cells, the recent advance in immunology and molecular biology has gradually revealed such target molecules. Specifically, it has been found that using T cell receptors (TCRs), CTL recognizes a complex between a peptide, called tumor antigen peptide, and a major histocompatibility complex class I antigen (MHC class I antigen, and in the case of human, referred to as HLA antigen), and thereby attacks autologous tumor cells.
Tumor antigen peptides are generated from proteins specific for tumors, that is, tumor antigen proteins. Thus, the proteins are intracellularly synthesized and then degraded in cytoplasm into the peptides by proteasome. On the other hand, MHC class I antigens (HLA antigens) formed at endoplasmic reticulum, when bind to the above tumor antigen peptides, are transported via cis Golgi to trans Golgi, i.e., the mature side and carried to the cell surface where they are presented as an antigen. A tumor-specific CTL recognizes this complex presented as an antigen, and exhibits its anti-tumor effects through the cytotoxic effect or production of lymphokines (
Rinsho
-
Menneki,
27(9):1034-1042, 1995). As a consequence of such elucidation of a series of actions, it has become possible to treat tumors by using tumor antigen proteins or tumor antigen peptides as so-called cancer vaccines which enhance tumor-specific CTLs in a patient.
As such tumor antigen proteins, T. Boon et al. identified a protein named MAGE from human melanoma cells for the first time in 1991 (
Science,
254:1643-1647, 1991), and thereafter several additional tumor antigen proteins have been identified from melanoma cells.
As reviewed by T. Boon et al. (
J. Exp. Med.,
183, 725-729, 1996), tumor antigen proteins hitherto identified can be divided into the following four categories.
Tumor antigen proteins belonging to the first category are those which are expressed in testis only as normal tissues, while they are expressed in melanoma, head and neck cancer, non-small cell lung cancer, bladder cancer and others, as tumor tissues. Among tumor antigen proteins in this category are the above-described MAGE and analogous proteins constituting a family of more than 12 members (
J. Exp. Med.,
178:489-495, 1993), as well as BAGE (
Immunity,
2:167-175, 1995) and GAGE (
J. Exp. Med.,
182:689-698, 1995), all of which have been identified in melanoma cells.
Although some of such tumor antigen proteins in this category are highly expressed in melanoma, the expression thereof is observed in only 10 to 30% of patients having a particular tumor other than melanoma, and therefore, they cannot be applied widely to treatments or diagnoses of various tumors.
Tumor antigen proteins belonging to the second category are those which are expressed only in melanocytes and retina among normal tissues, and in melanomas among tumor tissues. Since these tissue-specific proteins are highly expressed in melanomas, they would function as tumor antigen proteins specific for melanomas, Among tumor antigen proteins in this category are tyrosinase (
J. Exp. Med.,
178:489-495, 1993), MART-1 (
Proc. Natl. Acad. Sci. USA,
91:3515, 1994), gp100 (
J. Exp. Med.,
179:1005-1009, 1994), and gp75 (
J. Exp. Med.,
181:799-804, 1995). Genes encoding these proteins have all been cloned from melanoma cells. Melan-A (
J. Exp. Med.,
180:35, 1994), which has been separately isolated, has proved to be identical with MART-1.
However, the tumor antigen proteins of this category cannot be used widely in the treatments or diagnoses of various tumors, since they are not expressed in tumors other than melanoma.
Tumor antigen proteins belonging to the third category are those which are expressed as tumor antigen peptides recognized by CTL as a result of tumor-specific mutations. Among tumor antigen proteins in this category are mutated CDK4 (
Science,
269:1281-1284, 1995), &bgr;-catenin (
J. Exp. Med.,
183:1185-1192, 1996), and MUM-1 (
Proc. Natl. Acad. Sci. USA,
92:7976-7980, 1995). In CDK4 and &bgr;-catenin, a single amino acid mutation increases the binding affinity of the peptides to MHC class I antigen, which allows them to be recognized by T cells. In MUM-1, an intron, which normally is not translated, is translated due to mutation, and the resultant peptide is recognized by T cells. However, since such mutations occur at low frequency, they cannot be applied widely to treatments or diagnoses of various tumors.
Tumor antigen proteins belonging to the fourth category are those widely expressed in normal tissues and also recognized by CTL, example of which includes P15 identified from melanoma cells (
J. Immunol.
154:5944-5955, 1995).
Some of known tumor antigen proteins as described above are expressed only in limited tumors such as melanoma, and the others are expressed only in a small number of patients having a particular tumor even if they are expressed in various kinds of tumor, and therefore, they cannot be used widely in the treatments or diagnoses of various tumors. Accordingly, it is necessary to identify a tumor antigen that is widely applicable to various tumors, for instance, squamous cell carcinomas (e.g., esophageal cancer, lung cancer), which show much higher incidence than melanomas, before the application of tumor antigen proteins or tumor antigen peptides generated therefrom by intracellular degradation to the treatments or the diagnoses of various tumors. In this connection, the present inventors have conducted cloning of a gene encoding a tumor antigen protein from squamous cell carcinoma cells derived from esophageal cancer, and, for the first time, succeeded in cloning a gene encoding a tumor antigen protein (SART-1) from tumor cells other than melanomas (International Publication WO 97/46676).
Regarding diagnosis of tumors, various approaches are now being made by means of antibodies against tumor associated antigens, which, for example, include detection of antigenic substances in blood by radioimmunoassay, ELISA, or the like; histological cytodiagnosis by immunohistochemical methods such as enzyme-linked immunosorbent assay or fluorescent antibody technique; or imaging of tumors (Fishman, W. H. et al., “Oncodevelopmental Markers”, Academic Press, 1983). However, leading tumor markers currently used give a false positive in benign diseases with relatively high frequency. Therefore, there has been a great demand for the identification of a tumor antigen protein highly specific for tumors and the isolation of antibodies against the same to be used in diagnosis.
Furthermore, when using a particular tumor antigen protein or tumor antigen peptide as, for example, a vaccine, it is desired that a patient who expresses the tumor antigen protein and is possibly reactive to treatment with the tumor antigen protein/peptide is diagnosed and selected before applying the protein/peptide to the patient. Tumor antigen proteins with high tumor specificity or antibodies directed thereto are believed to be extremely useful diagnostic agents in the selection of such subject patients. From this point of view, it is desired
Imai Yasuhisa
Itoh Kyogo
Shichijo Shigeki
Birch & Stewart Kolasch & Birch, LLP
Caputa Anthony C.
Itoh Kyogo
Rawlings Stephen L.
LandOfFree
Tumor antigen protein, gene thereof, and utilization thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen protein, gene thereof, and utilization thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen protein, gene thereof, and utilization thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3050407